Optimization of the AAV Expression Using PATfix Analytical Platform

Ivana Petrović Koshmak, Head of Upstream Process Development, Sartorius BIA Separations

Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.

One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids. The most efficient way is to design the USP to result in less than 10% of empty capsids. This can be realised by process optimisation using at-line PATfix analytics to allow for analysis of the full and empty capsids ratio during the virus expression.

Fast and reliable at-line analytical methods to allow for process optimisation USP and DSP, and assessing the purity of the final product using PATfix system will be presented.

    Your Cart
    Your cart is emptyReturn to Shop
      This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.